drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00912 | DB01263 | 473 | 859 | [
"DDInter1581",
"DDInter1494"
] | Repaglinide | Posaconazole | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
473,
24,
859
]
],
[
[
473,
6,
8374
],
[
8374,
45,
859
]
],
[
[
473,
21,
28762
],
[
28762,
60,
859
]
],
[
[
473,
63,
1101
],
[
1101,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Repaglinide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and... |
DB00741 | DB00880 | 167 | 359 | [
"DDInter885",
"DDInter360"
] | Hydrocortisone | Chlorothiazide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
167,
24,
359
]
],
[
[
167,
24,
1577
],
[
1577,
1,
359
]
],
[
[
167,
63,
1014
],
[
1014,
1,
359
]
],
[
[
167,
21,
28748
],
[
28748,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiaz... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) ... |
DB00224 | DB08901 | 215 | 1,468 | [
"DDInter917",
"DDInter1492"
] | Indinavir | Ponatinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
215,
25,
1468
]
],
[
[
215,
25,
478
],
[
478,
24,
1468
]
],
[
[
215,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
215,
7,
7245
],
[
7245,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ca... | Indinavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Indinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Indinavir (Compound) upregulates SSBP2 ... |
DB01115 | DB11921 | 336 | 1,019 | [
"DDInter1291",
"DDInter492"
] | Nifedipine | Deflazacort | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
336,
24,
1019
]
],
[
[
336,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
336,
24,
761
],
[
761,
24,
1019
]
],
[
[
336,
63,
629
],
[
629,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagl... |
DB00046 | DB00612 | 1,179 | 1,121 | [
"DDInter940",
"DDInter216"
] | Insulin lispro | Bisoprolol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Moderate | 1 | [
[
[
1179,
24,
1121
]
],
[
[
1179,
24,
819
],
[
819,
40,
1121
]
],
[
[
1179,
24,
417
],
[
417,
23,
1121
]
],
[
[
1179,
24,
1479
],
[
1479,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that ... |
DB00668 | DB06335 | 874 | 761 | [
"DDInter652",
"DDInter1646"
] | Epinephrine | Saxagliptin | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
874,
24,
761
]
],
[
[
874,
6,
8374
],
[
8374,
45,
761
]
],
[
[
874,
21,
28722
],
[
28722,
60,
761
]
],
[
[
874,
24,
104
],
[
104,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Epinephrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Epinephrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Met... |
DB00420 | DB09080 | 508 | 144 | [
"DDInter1532",
"DDInter1331"
] | Promazine | Olodaterol | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
508,
24,
144
]
],
[
[
508,
25,
1011
],
[
1011,
24,
144
]
],
[
[
508,
24,
543
],
[
543,
24,
144
]
],
[
[
508,
40,
216
],
[
216,
2... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Promazine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a ... |
DB00619 | DB11995 | 1,419 | 1,634 | [
"DDInter909",
"DDInter143"
] | Imatinib | Avatrombopag | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Major | 2 | [
[
[
1419,
25,
1634
]
],
[
[
1419,
63,
1622
],
[
1622,
24,
1634
]
],
[
[
1419,
25,
759
],
[
759,
24,
1634
]
],
[
[
1419,
24,
851
],
[
851,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazo... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Imatinib may lead to a major life threatening interaction when taken with Primidone and Primidone may cause ... |
DB00450 | DB01001 | 78 | 688 | [
"DDInter603",
"DDInter1632"
] | Droperidol | Salbutamol | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
78,
24,
688
]
],
[
[
78,
24,
874
],
[
874,
24,
688
]
],
[
[
78,
25,
1148
],
[
1148,
63,
688
]
],
[
[
78,
21,
29118
],
[
29118,
6... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Droperidol may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may ... |
DB00382 | DB12332 | 62 | 1,619 | [
"DDInter1734",
"DDInter1626"
] | Tacrine | Rucaparib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
62,
24,
1619
]
],
[
[
62,
24,
112
],
[
112,
23,
1619
]
],
[
[
62,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
62,
23,
848
],
[
848,
24... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Pi... |
DB00281 | DB06372 | 608 | 259 | [
"DDInter1066",
"DDInter1594"
] | Lidocaine | Rilonacept | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
608,
24,
259
]
],
[
[
608,
24,
1619
],
[
1619,
63,
259
]
],
[
[
608,
24,
1565
],
[
1565,
24,
259
]
],
[
[
608,
23,
985
],
[
985,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam... |
DB00595 | DB09054 | 1,545 | 384 | [
"DDInter1374",
"DDInter905"
] | Oxytetracycline | Idelalisib | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1545,
24,
384
]
],
[
[
1545,
63,
305
],
[
305,
24,
384
]
],
[
[
1545,
24,
242
],
[
242,
63,
384
]
],
[
[
1545,
24,
954
],
[
954,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Esch... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Oxytetracycline may cause a moderate interaction that could exacerbat... |
DB00615 | DB11691 | 690 | 1,499 | [
"DDInter1589",
"DDInter1258"
] | Rifabutin | Naldemedine | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
690,
24,
1499
]
],
[
[
690,
24,
723
],
[
723,
24,
1499
]
],
[
[
690,
25,
1419
],
[
1419,
24,
1499
]
],
[
[
690,
25,
1406
],
[
1406,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Rifabutin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mod... |
DB00346 | DB00694 | 472 | 51 | [
"DDInter44",
"DDInter485"
] | Alfuzosin | Daunorubicin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
472,
24,
51
]
],
[
[
472,
6,
8374
],
[
8374,
45,
51
]
],
[
[
472,
7,
2216
],
[
2216,
46,
51
]
],
[
[
472,
18,
6718
],
[
6718,
57... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Daunorubicin (Compound)
Alfuzosin (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Daunorubicin (Compound)
Alfuzosin (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Daunorubicin (Compound)
Alfuzosin (Co... |
DB00472 | DB09020 | 758 | 28 | [
"DDInter758",
"DDInter212"
] | Fluoxetine | Bisacodyl | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
758,
24,
28
]
],
[
[
758,
24,
662
],
[
662,
1,
28
]
],
[
[
758,
63,
128
],
[
128,
40,
28
]
],
[
[
758,
24,
272
],
[
272,
40,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles B... |
DB00186 | DB01114 | 905 | 272 | [
"DDInter1092",
"DDInter362"
] | Lorazepam | Chlorpheniramine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
905,
24,
272
]
],
[
[
905,
40,
11275
],
[
11275,
1,
272
]
],
[
[
905,
24,
849
],
[
849,
63,
272
]
],
[
[
905,
24,
128
],
[
128,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Comp... | Lorazepam (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Chlorpheniramine (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01056 | DB08895 | 571 | 976 | [
"DDInter1823",
"DDInter1825"
] | Tocainide | Tofacitinib | An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
571,
24,
976
]
],
[
[
571,
74,
608
],
[
608,
24,
976
]
],
[
[
571,
40,
143
],
[
143,
24,
976
]
],
[
[
571,
24,
270
],
[
270,
64,... | [
[
[
"Tocainide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Tocainide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Tocainide (Compound) resembles Lidocaine (Compound) and Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Tocainide (Compound) resembles Mexiletine (Compound) and M... |
DB00427 | DB03128 | 1,233 | 140 | [
"DDInter1879",
"DDInter18"
] | Triprolidine | Acetylcholine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken ... | Moderate | 1 | [
[
[
1233,
24,
140
]
],
[
[
1233,
24,
1376
],
[
1376,
24,
140
]
],
[
[
1233,
63,
999
],
[
999,
24,
140
]
],
[
[
1233,
24,
1116
],
[
1116,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylcholine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Thie... |
DB00741 | DB09118 | 167 | 1,580 | [
"DDInter885",
"DDInter1711"
] | Hydrocortisone | Stiripentol | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
167,
24,
1580
]
],
[
[
167,
24,
283
],
[
283,
63,
1580
]
],
[
[
167,
24,
473
],
[
473,
24,
1580
]
],
[
[
167,
62,
1018
],
[
1018,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide ... |
DB08865 | DB09128 | 1,593 | 1,241 | [
"DDInter448",
"DDInter231"
] | Crizotinib | Brexpiprazole | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Major | 2 | [
[
[
1593,
25,
1241
]
],
[
[
1593,
63,
761
],
[
761,
24,
1241
]
],
[
[
1593,
25,
129
],
[
129,
24,
1241
]
],
[
[
1593,
24,
1662
],
[
1662,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagl... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide m... |
DB00855 | DB01017 | 213 | 1,669 | [
"DDInter72",
"DDInter1224"
] | Aminolevulinic acid | Minocycline | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Major | 2 | [
[
[
213,
25,
1669
]
],
[
[
213,
64,
1572
],
[
1572,
1,
1669
]
],
[
[
213,
64,
1605
],
[
1605,
23,
1669
]
],
[
[
213,
25,
504
],
[
504,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minocycline"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Demeclocycline"
],
[
"De... | Aminolevulinic acid may lead to a major life threatening interaction when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Indapamide and Indapamide may cause a minor interaction that can limit c... |
DB00618 | DB13257 | 1,572 | 260 | [
"DDInter498",
"DDInter727"
] | Demeclocycline | Ferrous sulfate anhydrous | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
1572,
24,
260
]
],
[
[
1572,
24,
1114
],
[
1114,
23,
260
]
],
[
[
1572,
24,
489
],
[
489,
24,
260
]
],
[
[
1572,
40,
1620
],
[
1620,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00372 | DB00844 | 999 | 314 | [
"DDInter1793",
"DDInter1257"
] | Thiethylperazine | Nalbuphine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
999,
24,
314
]
],
[
[
999,
24,
828
],
[
828,
40,
314
]
],
[
[
999,
63,
421
],
[
421,
1,
314
]
],
[
[
999,
63,
475
],
[
475,
25,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbup... |
DB00261 | DB00377 | 702 | 1,494 | [
"DDInter93",
"DDInter1382"
] | Anagrelide | Palonosetron | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Major | 2 | [
[
[
702,
25,
1494
]
],
[
[
702,
6,
7950
],
[
7950,
45,
1494
]
],
[
[
702,
21,
28723
],
[
28723,
60,
1494
]
],
[
[
702,
23,
112
],
[
112,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Palon... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Palonosetron (Compound)
Anagrelide (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Palonosetron (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB01006 | DB01039 | 300 | 535 | [
"DDInter1040",
"DDInter718"
] | Letrozole | Fenofibrate | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
300,
24,
535
]
],
[
[
300,
6,
8374
],
[
8374,
45,
535
]
],
[
[
300,
18,
10496
],
[
10496,
57,
535
]
],
[
[
300,
21,
28936
],
[
28936,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fenofibrate (Compound)
Letrozole (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Fenofibrate (Compound)
Letrozole (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fenofibrate (... |
DB01098 | DB09330 | 14 | 985 | [
"DDInter1622",
"DDInter1352"
] | Rosuvastatin | Osimertinib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
14,
24,
985
]
],
[
[
14,
63,
168
],
[
168,
23,
985
]
],
[
[
14,
63,
134
],
[
134,
24,
985
]
],
[
[
14,
24,
1040
],
[
1040,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vi... |
DB00675 | DB01039 | 888 | 535 | [
"DDInter1744",
"DDInter718"
] | Tamoxifen | Fenofibrate | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
888,
24,
535
]
],
[
[
888,
6,
3486
],
[
3486,
45,
535
]
],
[
[
888,
7,
6855
],
[
6855,
46,
535
]
],
[
[
888,
21,
28936
],
[
28936,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fenofibrate (Compound)
Tamoxifen (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Fenofibrate (Compound)
Tamoxifen (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fenofibrate (Comp... |
DB09034 | DB09330 | 1,313 | 985 | [
"DDInter1733",
"DDInter1352"
] | Suvorexant | Osimertinib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1313,
24,
985
]
],
[
[
1313,
63,
1478
],
[
1478,
24,
985
]
],
[
[
1313,
24,
119
],
[
119,
63,
985
]
],
[
[
1313,
25,
283
],
[
283,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazo... |
DB00872 | DB08901 | 1,080 | 1,468 | [
"DDInter438",
"DDInter1492"
] | Conivaptan | Ponatinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1080,
25,
1468
]
],
[
[
1080,
25,
478
],
[
478,
24,
1468
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
1468
]
],
[
[
1080,
21,
29024
],
[
2902... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Conivaptan may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Conivaptan (Compound) causes Hyperten... |
DB00245 | DB01010 | 357 | 61 | [
"DDInter181",
"DDInter622"
] | Benzatropine | Edrophonium | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
357,
24,
61
]
],
[
[
357,
24,
1636
],
[
1636,
1,
61
]
],
[
[
357,
21,
28658
],
[
28658,
60,
61
]
],
[
[
357,
24,
1511
],
[
1511,
... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Edrophonium (Compound)
Benzatropine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Edrophonium (Compound)
Benzatropine may cause a moderate ... |
DB06168 | DB15965 | 1,531 | 1,330 | [
"DDInter281",
"DDInter1270"
] | Canakinumab | Naxitamab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1531,
24,
1330
]
],
[
[
1531,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
1531,
63,
1532
],
[
1532,
24,
1330
]
],
[
[
1531,
24,
259
],
[
259... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[... | Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and I... |
DB00087 | DB08826 | 599 | 1,292 | [
"DDInter41",
"DDInter489"
] | Alemtuzumab | Deferiprone | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
599,
25,
1292
]
],
[
[
599,
24,
482
],
[
482,
25,
1292
]
],
[
[
599,
63,
273
],
[
273,
25,
1292
]
],
[
[
599,
24,
1619
],
[
1619,
... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguan... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab and Tositumomab may l... |
DB00092 | DB00495 | 58 | 139 | [
"DDInter40",
"DDInter1961"
] | Alefacept | Zidovudine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
58,
24,
139
]
],
[
[
58,
24,
1083
],
[
1083,
24,
139
]
],
[
[
58,
24,
309
],
[
309,
63,
139
]
],
[
[
58,
63,
669
],
[
669,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixa... |
DB00222 | DB00731 | 245 | 1,144 | [
"DDInter825",
"DDInter1269"
] | Glimepiride | Nateglinide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
245,
24,
1144
]
],
[
[
245,
24,
610
],
[
610,
24,
1144
]
],
[
[
245,
63,
168
],
[
168,
24,
1144
]
],
[
[
245,
5,
11640
],
[
11640,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Borte... |
DB00222 | DB06077 | 245 | 879 | [
"DDInter825",
"DDInter1102"
] | Glimepiride | Lumateperone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
245,
24,
879
]
],
[
[
245,
24,
1281
],
[
1281,
63,
879
]
],
[
[
245,
24,
1645
],
[
1645,
24,
879
]
],
[
[
245,
25,
86
],
[
86,
2... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metformin and M... |
DB01156 | DB09039 | 593 | 1,670 | [
"DDInter252",
"DDInter629"
] | Bupropion | Eliglustat | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
593,
25,
1670
]
],
[
[
593,
64,
479
],
[
479,
23,
1670
]
],
[
[
593,
62,
211
],
[
211,
23,
1670
]
],
[
[
593,
64,
121
],
[
121,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may c... | Bupropion may lead to a major life threatening interaction when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Bupropion may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a mino... |
DB08820 | DB09272 | 1,478 | 412 | [
"DDInter997",
"DDInter632"
] | Ivacaftor | Eluxadoline | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1478,
24,
412
]
],
[
[
1478,
25,
74
],
[
74,
24,
412
]
],
[
[
1478,
63,
1131
],
[
1131,
24,
412
]
],
[
[
1478,
64,
441
],
[
441,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
],
[
"Boceprevir"... | Ivacaftor may lead to a major life threatening interaction when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide may cau... |
DB00047 | DB00584 | 176 | 610 | [
"DDInter932",
"DDInter638"
] | Insulin glargine | Enalapril | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
176,
24,
610
]
],
[
[
176,
24,
743
],
[
743,
1,
610
]
],
[
[
176,
24,
954
],
[
954,
40,
610
]
],
[
[
176,
24,
590
],
[
590,
24,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril (Co... |
DB01073 | DB08913 | 1,488 | 1,186 | [
"DDInter745",
"DDInter1561"
] | Fludarabine | Radium Ra 223 dichloride | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1488,
24,
1186
]
],
[
[
1488,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
1488,
24,
37
],
[
37,
24,
1186
]
],
[
[
1488,
63,
134
],
[
134,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Fludarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effec... | Fludarabine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00794 | DB01259 | 759 | 392 | [
"DDInter1521",
"DDInter1024"
] | Primidone | Lapatinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
759,
24,
392
]
],
[
[
759,
6,
8374
],
[
8374,
45,
392
]
],
[
[
759,
21,
28883
],
[
28883,
60,
392
]
],
[
[
759,
25,
1135
],
[
1135,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Primidone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Lapatinib (Compound)
Primidone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cau... |
DB00344 | DB01211 | 1,302 | 609 | [
"DDInter1543",
"DDInter393"
] | Protriptyline | Clarithromycin | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1302,
24,
609
]
],
[
[
1302,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1302,
21,
28662
],
[
28662,
60,
609
]
],
[
[
1302,
63,
600
],
[
600,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Com... | Protriptyline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Protriptyline (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazol... |
DB00086 | DB00758 | 1,167 | 1,347 | [
"DDInter1712",
"DDInter413"
] | Streptokinase | Clopidogrel | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
1167,
24,
1347
]
],
[
[
1167,
24,
1018
],
[
1018,
25,
1347
]
],
[
[
1167,
23,
539
],
[
539,
62,
1347
]
],
[
[
1167,
24,
958
],
[
958,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cau... |
DB00067 | DB00927 | 317 | 1,559 | [
"DDInter1921",
"DDInter712"
] | Vasopressin | Famotidine | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
317,
24,
1559
]
],
[
[
317,
24,
1274
],
[
1274,
23,
1559
]
],
[
[
317,
23,
112
],
[
112,
23,
1559
]
],
[
[
317,
24,
848
],
[
848,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Famotidine
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00270 | DB01110 | 1,428 | 86 | [
"DDInter993",
"DDInter1209"
] | Isradipine | Miconazole | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1428,
24,
86
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
86
]
],
[
[
1428,
21,
29122
],
[
29122,
60,
86
]
],
[
[
1428,
24,
1101
],
[
1101,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Miconazole (Compound)
Isradipine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00108 | DB05015 | 1,066 | 1,077 | [
"DDInter1268",
"DDInter174"
] | Natalizumab | Belinostat | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Major | 2 | [
[
[
1066,
25,
1077
]
],
[
[
1066,
25,
482
],
[
482,
24,
1077
]
],
[
[
1066,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
1066,
64,
58
],
[
58,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u}... | Natalizumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause ... |
DB00712 | DB00749 | 1,274 | 59 | [
"DDInter763",
"DDInter699"
] | Flurbiprofen | Etodolac | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
1274,
24,
59
]
],
[
[
1274,
6,
6017
],
[
6017,
45,
59
]
],
[
[
1274,
10,
11666
],
[
11666,
49,
59
]
],
[
[
1274,
54,
19122
],
[
19122,... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Flurbiprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etodolac (Compound)
Flurbiprofen (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Etodolac (Compound)
Flurbiprofen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) ... |
DB11689 | DB11730 | 321 | 351 | [
"DDInter1659",
"DDInter1588"
] | Selumetinib | Ribociclib | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
321,
25,
351
]
],
[
[
321,
25,
283
],
[
283,
62,
351
]
],
[
[
321,
64,
597
],
[
597,
24,
351
]
],
[
[
321,
63,
951
],
[
951,
24,... | [
[
[
"Selumetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Selumetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u}... | Selumetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Selumetinib may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a mod... |
DB00912 | DB09272 | 473 | 412 | [
"DDInter1581",
"DDInter632"
] | Repaglinide | Eluxadoline | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
473,
24,
412
]
],
[
[
473,
24,
824
],
[
824,
23,
412
]
],
[
[
473,
24,
74
],
[
74,
24,
412
]
],
[
[
473,
63,
441
],
[
441,
24,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a minor interaction that can limit clinical effects when taken with Eluxadoline
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir and Bocep... |
DB00215 | DB00719 | 1,230 | 1,219 | [
"DDInter388",
"DDInter149"
] | Citalopram | Azatadine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1230,
24,
1219
]
],
[
[
1230,
24,
13
],
[
13,
24,
1219
]
],
[
[
1230,
24,
830
],
[
830,
1,
1219
]
],
[
[
1230,
6,
8374
],
[
8374,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine a... |
DB00912 | DB14751 | 473 | 388 | [
"DDInter1581",
"DDInter1132"
] | Repaglinide | Mecasermin rinfabate | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin rinfabate is similar to in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin... | Moderate | 1 | [
[
[
473,
24,
388
]
],
[
[
473,
63,
610
],
[
610,
24,
1144
],
[
1144,
24,
388
]
],
[
[
473,
5,
11640
],
[
11640,
44,
1144
],
[
1144,
24,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin rinfabate"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfa... |
DB00865 | DB00907 | 939 | 290 | [
"DDInter187",
"DDInter427"
] | Benzphetamine | Cocaine (topical) | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Major | 2 | [
[
[
939,
25,
290
]
],
[
[
939,
6,
2437
],
[
2437,
45,
290
]
],
[
[
939,
21,
28741
],
[
28741,
60,
290
]
],
[
[
939,
24,
629
],
[
629,
... | [
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Benzphetamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compound)",
"Coca... | Benzphetamine may lead to a major life threatening interaction when taken with Cocaine
Benzphetamine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Cocaine (Compound)
Benzphetamine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Cocaine (Compound)
Benzphetamine may cause... |
DB01124 | DB01299 | 1,411 | 698 | [
"DDInter1828",
"DDInter1722"
] | Tolbutamide | Sulfadoxine | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
1411,
24,
698
]
],
[
[
1411,
63,
1247
],
[
1247,
40,
698
]
],
[
[
1411,
63,
161
],
[
161,
1,
698
]
],
[
[
1411,
1,
11259
],
[
11259,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sul... |
DB00414 | DB01238 | 590 | 673 | [
"DDInter16",
"DDInter118"
] | Acetohexamide | Aripiprazole | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
590,
24,
673
]
],
[
[
590,
24,
1630
],
[
1630,
1,
673
]
],
[
[
590,
64,
600
],
[
600,
24,
673
]
],
[
[
590,
24,
1424
],
[
1424,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could ... |
DB11837 | DB12267 | 1,297 | 1,476 | [
"DDInter1351",
"DDInter233"
] | Osilodrostat | Brigatinib | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1297,
24,
1476
]
],
[
[
1297,
63,
1612
],
[
1612,
23,
1476
]
],
[
[
1297,
62,
1135
],
[
1135,
23,
1476
]
],
[
[
1297,
24,
230
],
[
230... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Nalox... |
DB00572 | DB00999 | 85 | 504 | [
"DDInter136",
"DDInter883"
] | Atropine | Hydrochlorothiazide | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Minor | 0 | [
[
[
85,
23,
504
]
],
[
[
85,
23,
178
],
[
178,
1,
504
]
],
[
[
85,
62,
323
],
[
323,
40,
504
]
],
[
[
85,
23,
359
],
[
359,
40,
... | [
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
],
[... | Atropine may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Atropine may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles... |
DB00467 | DB00682 | 1,467 | 126 | [
"DDInter644",
"DDInter1951"
] | Enoxacin | Warfarin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1467,
25,
126
]
],
[
[
1467,
6,
7950
],
[
7950,
45,
126
]
],
[
[
1467,
24,
135
],
[
135,
62,
126
]
],
[
[
1467,
23,
1001
],
[
1001,
... | [
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Enoxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
... | Enoxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Enoxacin may cause a minor... |
DB00176 | DB00514 | 529 | 506 | [
"DDInter770",
"DDInter527"
] | Fluvoxamine | Dextromethorphan | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Major | 2 | [
[
[
529,
25,
506
]
],
[
[
529,
6,
8374
],
[
8374,
45,
506
]
],
[
[
529,
21,
28750
],
[
28750,
60,
506
]
],
[
[
529,
24,
741
],
[
741,
... | [
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound)
Fluvoxamine (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Dextromethorphan (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate disease... |
DB00163 | DB06372 | 1,461 | 259 | [
"DDInter1943",
"DDInter1594"
] | Vitamin E | Rilonacept | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Minor | 0 | [
[
[
1461,
23,
259
]
],
[
[
1461,
24,
0
],
[
0,
24,
259
]
],
[
[
1461,
23,
1573
],
[
1573,
24,
259
]
],
[
[
1461,
23,
1093
],
[
1093,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rilonacept"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Prednisone and Predni... |
DB00601 | DB01619 | 453 | 830 | [
"DDInter1073",
"DDInter1441"
] | Linezolid | Phenindamine | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
453,
24,
830
]
],
[
[
453,
24,
537
],
[
537,
40,
830
]
],
[
[
453,
63,
13
],
[
13,
24,
830
]
],
[
[
453,
24,
104
],
[
104,
1,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that... |
DB00461 | DB01254 | 598 | 1,213 | [
"DDInter1254",
"DDInter484"
] | Nabumetone | Dasatinib | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
598,
25,
1213
]
],
[
[
598,
6,
7950
],
[
7950,
45,
1213
]
],
[
[
598,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
598,
24,
738
],
[
738,
... | [
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Nabumetone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatini... | Nabumetone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dasatinib (Compound)
Nabumetone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases whe... |
DB00626 | DB01199 | 1,441 | 1,217 | [
"DDInter161",
"DDInter1890"
] | Bacitracin | Tubocurarine | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Tubocurarine is a non-depolarizing neuromuscular blocking agent and the first identified curare alkaloid. Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to coat the tips of hunting arrows and darts, which were typically derived from plants of the genera _Chondrodend... | Moderate | 1 | [
[
[
1441,
24,
1217
]
],
[
[
1441,
24,
545
],
[
545,
1,
1217
]
],
[
[
1441,
7,
5727
],
[
5727,
46,
1217
]
],
[
[
1441,
63,
91
],
[
91,
... | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
],
[
... | Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Metocurine and Metocurine (Compound) resembles Tubocurarine (Compound)
Bacitracin (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Tubocurarine (Compound)
Bacitracin may cause a moderate interaction that could... |
DB00759 | DB14491 | 1,620 | 428 | [
"DDInter1783",
"DDInter725"
] | Tetracycline | Ferrous fumarate | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1620,
24,
428
]
],
[
[
1620,
24,
1096
],
[
1096,
23,
428
]
],
[
[
1620,
63,
955
],
[
955,
23,
428
]
],
[
[
1620,
1,
1572
],
[
1572,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01001 | DB01142 | 688 | 1,264 | [
"DDInter1632",
"DDInter593"
] | Salbutamol | Doxepin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
688,
24,
1264
]
],
[
[
688,
63,
508
],
[
508,
24,
1264
]
],
[
[
688,
24,
401
],
[
401,
24,
1264
]
],
[
[
688,
6,
8374
],
[
8374,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethaz... |
DB00401 | DB06372 | 84 | 259 | [
"DDInter1298",
"DDInter1594"
] | Nisoldipine | Rilonacept | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
84,
24,
259
]
],
[
[
84,
24,
1619
],
[
1619,
63,
259
]
],
[
[
84,
24,
1573
],
[
1573,
24,
259
]
],
[
[
84,
1,
409
],
[
409,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Predni... |
DB08886 | DB08916 | 637 | 26 | [
"DDInter126",
"DDInter32"
] | Asparaginase Erwinia chrysanthemi | Afatinib | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
637,
24,
26
]
],
[
[
637,
63,
883
],
[
883,
40,
26
]
],
[
[
637,
63,
79
],
[
79,
24,
26
]
],
[
[
637,
24,
384
],
[
384,
63,
... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may... |
DB00938 | DB11978 | 455 | 124 | [
"DDInter1635",
"DDInter822"
] | Salmeterol | Glasdegib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
455,
24,
124
]
],
[
[
455,
24,
327
],
[
327,
24,
124
]
],
[
[
455,
24,
1032
],
[
1032,
63,
124
]
],
[
[
455,
63,
79
],
[
79,
24,... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Lev... |
DB00470 | DB00494 | 530 | 1,533 | [
"DDInter601",
"DDInter646"
] | Dronabinol | Entacapone | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Moderate | 1 | [
[
[
530,
24,
1533
]
],
[
[
530,
63,
1062
],
[
1062,
1,
1533
]
],
[
[
530,
21,
28769
],
[
28769,
60,
1533
]
],
[
[
530,
24,
770
],
[
770,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Dronabinol (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Entacapone (Compound)
Dronabinol may cause a moderate ... |
DB05239 | DB12457 | 866 | 1,180 | [
"DDInter425",
"DDInter1598"
] | Cobimetinib | Rimegepant | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
866,
24,
1180
]
],
[
[
866,
24,
741
],
[
741,
24,
1180
]
],
[
[
866,
64,
1419
],
[
1419,
24,
1180
]
],
[
[
866,
25,
351
],
[
351,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a ... |
DB01045 | DB08865 | 463 | 1,593 | [
"DDInter1590",
"DDInter448"
] | Rifampicin | Crizotinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
463,
25,
1593
]
],
[
[
463,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
463,
25,
283
],
[
283,
62,
1593
]
],
[
[
463,
63,
883
],
[
883,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizoti... | Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Rifampicin may cause a moderate int... |
DB01105 | DB01209 | 222 | 1,359 | [
"DDInter1665",
"DDInter531"
] | Sibutramine | Dezocine | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
222,
24,
1359
]
],
[
[
222,
64,
234
],
[
234,
1,
1359
]
],
[
[
222,
63,
717
],
[
717,
24,
1359
]
],
[
[
222,
64,
1494
],
[
1494,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
],
[
"Pentazoci... | Sibutramine may lead to a major life threatening interaction when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that coul... |
DB00747 | DB06077 | 1,442 | 879 | [
"DDInter1647",
"DDInter1102"
] | Scopolamine | Lumateperone | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
1442,
24,
879
]
],
[
[
1442,
24,
407
],
[
407,
63,
879
]
],
[
[
1442,
24,
1511
],
[
1511,
24,
879
]
],
[
[
1442,
63,
999
],
[
999,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate... |
DB00555 | DB01233 | 706 | 1,311 | [
"DDInter1020",
"DDInter1197"
] | Lamotrigine | Metoclopramide | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
706,
24,
1311
]
],
[
[
706,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
706,
63,
1010
],
[
1010,
23,
1311
]
],
[
[
706,
24,
649
],
[
649,
... | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect)... | Lamotrigine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with M... |
DB00222 | DB01142 | 245 | 1,264 | [
"DDInter825",
"DDInter593"
] | Glimepiride | Doxepin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
245,
24,
1264
]
],
[
[
245,
24,
508
],
[
508,
24,
1264
]
],
[
[
245,
6,
6017
],
[
6017,
45,
1264
]
],
[
[
245,
21,
28803
],
[
28803,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Doxepin (Compound)
Glimepiride (Compound) c... |
DB01131 | DB08938 | 1,243 | 1,384 | [
"DDInter1531",
"DDInter1112"
] | Proguanil | Magaldrate | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1243,
24,
1384
]
],
[
[
1243,
63,
954
],
[
954,
23,
1384
]
],
[
[
1243,
63,
929
],
[
929,
24,
1384
]
],
[
[
1243,
63,
954
],
[
954,
... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
... | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimetha... |
DB00679 | DB00804 | 684 | 1,507 | [
"DDInter1796",
"DDInter543"
] | Thioridazine | Dicyclomine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
684,
24,
1507
]
],
[
[
684,
6,
4304
],
[
4304,
45,
1507
]
],
[
[
684,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
684,
24,
1021
],
[
1021,... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound... | Thioridazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Dicyclomine (Compound)
Thioridazine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Pra... |
DB00543 | DB01075 | 87 | 1,376 | [
"DDInter82",
"DDInter569"
] | Amoxapine | Diphenhydramine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
87,
24,
1376
]
],
[
[
87,
24,
649
],
[
649,
63,
1376
]
],
[
[
87,
64,
11
],
[
11,
1,
1376
]
],
[
[
87,
63,
128
],
[
128,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Amoxapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compou... |
DB09330 | DB14783 | 985 | 287 | [
"DDInter1352",
"DDInter574"
] | Osimertinib | Diroximel fumarate | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
985,
24,
287
]
],
[
[
985,
63,
1101
],
[
1101,
24,
287
]
],
[
[
985,
64,
384
],
[
384,
24,
287
]
],
[
[
985,
25,
1619
],
[
1619,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Osimertinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib ... |
DB00883 | DB01075 | 426 | 1,376 | [
"DDInter989",
"DDInter569"
] | Isosorbide dinitrate | Diphenhydramine | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
426,
24,
1376
]
],
[
[
426,
24,
401
],
[
401,
24,
1376
]
],
[
[
426,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
426,
63,
530
],
[
530,
... | [
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pr... | Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Isosorbide dinitrate (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is... |
DB01764 | DB08899 | 805 | 129 | [
"DDInter469",
"DDInter649"
] | Dalfopristin | Enzalutamide | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
805,
24,
129
]
],
[
[
805,
6,
8374
],
[
8374,
45,
129
]
],
[
[
805,
63,
608
],
[
608,
23,
129
]
],
[
[
805,
63,
147
],
[
147,
24... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Dalfopristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Dalfopristin m... |
DB01403 | DB11901 | 9 | 913 | [
"DDInter1175",
"DDInter107"
] | Methotrimeprazine | Apalutamide | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
9,
24,
913
]
],
[
[
9,
62,
112
],
[
112,
23,
913
]
],
[
[
9,
63,
600
],
[
600,
24,
913
]
],
[
[
9,
24,
28
],
[
28,
24,
913... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"... | Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Fluc... |
DB00543 | DB06704 | 87 | 247 | [
"DDInter82",
"DDInter952"
] | Amoxapine | Iobenguane (I-131) | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
87,
37,
247
]
],
[
[
87,
6,
7390
],
[
7390,
45,
247
]
],
[
[
87,
21,
28787
],
[
28787,
60,
247
]
],
[
[
87,
40,
1408
],
[
1408,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Amoxapine may lead to a major life threatening interaction when taken with Iobenguane
Amoxapine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Amoxapine (Compound) causes Dermatit... |
DB09065 | DB11921 | 760 | 1,019 | [
"DDInter424",
"DDInter492"
] | Cobicistat | Deflazacort | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
760,
25,
1019
]
],
[
[
760,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
760,
63,
761
],
[
761,
24,
1019
]
],
[
[
760,
64,
629
],
[
629,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib"... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagl... |
DB06636 | DB08911 | 1,623 | 1,556 | [
"DDInter980",
"DDInter1842"
] | Isavuconazonium | Trametinib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Moderate | 1 | [
[
[
1623,
24,
1556
]
],
[
[
1623,
25,
384
],
[
384,
63,
1556
]
],
[
[
1623,
24,
1320
],
[
1320,
63,
1556
]
],
[
[
1623,
25,
129
],
[
129,
... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trametinib"
]
],
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"... | Isavuconazonium may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Trametinib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may ... |
DB00775 | DB08896 | 1,226 | 292 | [
"DDInter1818",
"DDInter1576"
] | Tirofiban | Regorafenib | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1226,
25,
292
]
],
[
[
1226,
21,
28890
],
[
28890,
60,
292
]
],
[
[
1226,
24,
643
],
[
643,
24,
292
]
],
[
[
1226,
63,
109
],
[
109,
... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Tirofiban",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
"{u} (Side Effect)... | Tirofiban (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate d... |
DB00022 | DB01394 | 268 | 1,554 | [
"DDInter1408",
"DDInter431"
] | Peginterferon alfa-2b | Colchicine | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
268,
24,
1554
]
],
[
[
268,
24,
367
],
[
367,
24,
1554
]
],
[
[
268,
24,
375
],
[
375,
63,
1554
]
],
[
[
268,
63,
1057
],
[
1057,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Inter... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate dise... |
DB01087 | DB08865 | 1,520 | 1,593 | [
"DDInter1520",
"DDInter448"
] | Primaquine | Crizotinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1520,
25,
1593
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1520,
21,
28658
],
[
28658,
60,
1593
]
],
[
[
1520,
62,
479
],
[
47... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizoti... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Primaquine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Crizotinib (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil... |
DB00242 | DB00987 | 1,064 | 1,224 | [
"DDInter392",
"DDInter460"
] | Cladribine | Cytarabine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Major | 2 | [
[
[
1064,
37,
1224
]
],
[
[
1064,
40,
1049
],
[
1049,
1,
1224
]
],
[
[
1064,
1,
325
],
[
325,
40,
1224
]
],
[
[
1064,
1,
1585
],
[
1585,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound)",
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and
Cladribine (Compound) resembles Regadenoson (Compound) and Regadenoson (Compound) resembles Cytarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Cytarabine... |
DB00069 | DB01156 | 367 | 593 | [
"DDInter946",
"DDInter252"
] | Interferon alfacon-1 | Bupropion | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
367,
25,
593
]
],
[
[
367,
24,
996
],
[
996,
63,
593
]
],
[
[
367,
24,
126
],
[
126,
24,
593
]
],
[
[
367,
23,
450
],
[
450,
24,... | [
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01105 | DB08918 | 222 | 41 | [
"DDInter1665",
"DDInter1059"
] | Sibutramine | Levomilnacipran | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Major | 2 | [
[
[
222,
25,
41
]
],
[
[
222,
25,
901
],
[
901,
40,
41
]
],
[
[
222,
64,
1349
],
[
1349,
40,
41
]
],
[
[
222,
6,
6112
],
[
6112,
45,... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
... | Sibutramine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Levomilnacipran (Compound)
Sibutramine (Com... |
DB00005 | DB11627 | 1,057 | 1,367 | [
"DDInter687",
"DDInter860"
] | Etanercept | Hepatitis B Vaccine (Recombinant) | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1057,
24,
1367
]
],
[
[
1057,
25,
1083
],
[
1083,
24,
1367
]
],
[
[
1057,
25,
119
],
[
119,
63,
1367
]
],
[
[
1057,
24,
66
],
[
66,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
]... | Etanercept may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Etanercept may lead to a major life threatening interaction when taken with Talazoparib and Talazopa... |
DB00550 | DB00563 | 99 | 663 | [
"DDInter1541",
"DDInter1174"
] | Propylthiouracil | Methotrexate | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
99,
24,
663
]
],
[
[
99,
7,
2969
],
[
2969,
46,
663
]
],
[
[
99,
18,
6929
],
[
6929,
57,
663
]
],
[
[
99,
21,
29305
],
[
29305,
... | [
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Propylthiouracil",
"{u} (Compound) upregulates {v} (Gene)",
"CDKN1A"
],
[
"CDKN1A",
"{u} (Gene) is upreg... | Propylthiouracil (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Methotrexate (Compound)
Propylthiouracil (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Methotrexate (Compound)
Propylthiouracil (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is ... |
DB00224 | DB09330 | 215 | 985 | [
"DDInter917",
"DDInter1352"
] | Indinavir | Osimertinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
215,
25,
985
]
],
[
[
215,
63,
168
],
[
168,
23,
985
]
],
[
[
215,
24,
608
],
[
608,
23,
985
]
],
[
[
215,
25,
1478
],
[
1478,
2... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib"... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine ... |
DB06335 | DB14730 | 761 | 1,412 | [
"DDInter1646",
"DDInter264"
] | Saxagliptin | Calaspargase pegol | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
761,
24,
1412
]
],
[
[
761,
24,
159
],
[
159,
24,
1412
]
],
[
[
761,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
761,
64,
1101
],
[
1101,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Nateg... |
DB04865 | DB11703 | 4 | 405 | [
"DDInter1335",
"DDInter9"
] | Omacetaxine mepesuccinate | Acalabrutinib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
4,
25,
405
]
],
[
[
4,
63,
1324
],
[
1324,
24,
405
]
],
[
[
4,
24,
951
],
[
951,
24,
405
]
],
[
[
4,
25,
1598
],
[
1598,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitaz... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases ... |
DB00485 | DB01017 | 916 | 1,669 | [
"DDInter541",
"DDInter1224"
] | Dicloxacillin | Minocycline | One of the penicillins which is resistant to penicillinase. | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
916,
24,
1669
]
],
[
[
916,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
916,
63,
964
],
[
964,
1,
1669
]
],
[
[
916,
24,
1545
],
[
1545,
... | [
[
[
"Dicloxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Dicloxacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
... | Dicloxacillin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Dicloxacillin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Minoc... |
DB08873 | DB11979 | 74 | 1,320 | [
"DDInter221",
"DDInter625"
] | Boceprevir | Elagolix | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
74,
25,
1320
]
],
[
[
74,
63,
168
],
[
168,
23,
1320
]
],
[
[
74,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
74,
24,
26
],
[
26,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Boceprevir may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause ... |
DB00060 | DB01039 | 912 | 535 | [
"DDInter947",
"DDInter718"
] | Interferon beta-1a | Fenofibrate | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
912,
24,
535
]
],
[
[
912,
24,
831
],
[
831,
1,
535
]
],
[
[
912,
24,
522
],
[
522,
24,
535
]
],
[
[
912,
24,
187
],
[
187,
63,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethac... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate... |
DB00556 | DB00604 | 1,262 | 1,425 | [
"DDInter1429",
"DDInter385"
] | Perflutren | Cisapride | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
1262,
25,
1425
]
],
[
[
1262,
23,
112
],
[
112,
62,
1425
]
],
[
[
1262,
24,
603
],
[
603,
63,
1425
]
],
[
[
1262,
24,
355
],
[
355,
... | [
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cisapride
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate an... |
DB00580 | DB01250 | 311 | 712 | [
"DDInter1910",
"DDInter1334"
] | Valdecoxib | Olsalazine | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
311,
24,
712
]
],
[
[
311,
24,
50
],
[
50,
40,
712
]
],
[
[
311,
24,
126
],
[
126,
23,
712
]
],
[
[
311,
24,
416
],
[
416,
24,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can li... |
DB00762 | DB01263 | 613 | 859 | [
"DDInter973",
"DDInter1494"
] | Irinotecan | Posaconazole | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
613,
25,
859
]
],
[
[
613,
6,
4973
],
[
4973,
45,
859
]
],
[
[
613,
21,
28762
],
[
28762,
60,
859
]
],
[
[
613,
63,
1101
],
[
1101,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Posacon... | Irinotecan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Irinotecan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.